Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Genetic risk knowledge alone fails to curb obesity, study shows

11

Jul 2026

Genetic risk knowledge alone fails to curb obesity, study shows

Does informing people about their genetic risk of obesity help them change their habits and lose excess weight? A study, published in the journal Obesity Reviews by scientists including researchers from SWPS University, shows that knowledge about one's genes alone is not enough.

Insurance denials for brand-name drugs surge over past six years

11

Jul 2026

Insurance denials for brand-name drugs surge over past six years

A new study led by researchers at the Johns Hopkins Bloomberg School of Public Health and the American Enterprise Institute found that insurance denials of first attempts to fill prescriptions for brand-name prescription drugs with no generic competitors increased more than two-thirds between 2018 and 2024.

New grant funds Penn State street medicine program for homeless populations

11

Jul 2026

New grant funds Penn State street medicine program for homeless populations

Delivering healthcare services directly to people experiencing homelessness and training the next generation of physicians in street medicine is the goal of a new five-year, $2.5 million grant from the Human Resources and Services Administration, an agency within the U.S. Department of Health and Human Services, to Penn State College of Medicine.

New generation approaches revive BET protein inhibitors in solid tumors

11

Jul 2026

New generation approaches revive BET protein inhibitors in solid tumors

BET proteins, especially BRD4, drive oncogenic transcription in solid tumours. First‑generation inhibitors (JQ1, molibresib, birabresib) showed preclinical promise but failed clinically due to modest efficacy, dose‑limiting thrombocytopenia, and resistance (isoform switching, compensatory PI3K/AKT/WNT signalling).

New study explains how brain tumors evolve to resist treatment

11

Jul 2026

New study explains how brain tumors evolve to resist treatment

A form of glioma, a type of brain cancer, tends to progress towards greater malignancy due to an increasing tendency of the glioma cells to transform into immature, stem-cell-like states, according to a study led by investigators at Weill Cornell Medicine, the New York Genome Center, Harvard Medical School and Mass General Brigham.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.